Georgia's Online Cancer Information Center

Find A Clinical Trial

Registry of patients that have received the Caris Target Now and/or hematopoietic diagnostic testing

Status
Active
Cancer Type
Multiple Primaries
Trial Phase
Eligibility
Patients who previously have undergone Caris Targe, Male and Female
Study Type
Diagnostic
NCT ID
Caris
Protocol IDs
Caris (primary)
Study Sponsor
Caris Life Sciences
NCI Full Details

Summary

"A Registry of Caris Target Now Test Results (Biomarker Expression Patterns) for Evaluation of Correlation with Clinical Outcomes for Cancer and other Patients" is a multi-center, observational outcomes database designed to collect data on the demographics, presentation, diagnosis, treatment, resource use, and outcomes of eligible patients who previously have undergone Caris Target Now testing for treatment of solid tumor cancer.

 

Objectives

The registry is a mechanism by which eligible patients can choose to participate through their physicians in cancer research. By contributing patients' data, physicians and patients gain the knowledge that future patients with similar disease profiles may benefit from the experiences of the patients that contributed information before them.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.